Healthcare Market Shifts: Ground View

Q1. Could you start by giving us a brief overview of your professional background, particularly focusing on your expertise in the industry?

I’ve been working in the pharmaceutical industry for over 15 years now, mostly in hospital and critical care segments across North India. Currently, I lead the North region for Intas Pharmaceuticals, where I handle both strategy and execution for critical care, anti-infectives, and specialty therapies. My role keeps me very close to what’s actually happening on the ground.

Over the years, I’ve spent a lot of time working with hospital teams, whether it’s business development, managing key accounts, or dealing with market access. When you work closely with procurement heads and clinicians, you start to understand how decisions really get made. It’s never just about price or just about clinical value. There are always multiple factors at play, including regulatory requirements, and they all come together during procurement. Dealing with these situations regularly has shaped how I look at the healthcare system in India.

Q2. Following the January 2026 Schedule M enforcement, several 'Tier-2' local manufacturers in your UP and Haryana clusters have reportedly paused operations due to non-compliance. Have you seen an immediate 'Compliance Premium' emerge in…